Novel tumor marker index combining carcinoembryonic antigen and carbohydrate antigen 19-9: New prognostic factor for metastatic colorectal cancer

Basit Öğe Kaydı
dc.authorid0009-0003-8254-5417
dc.authorid0000-0003-4380-9419
dc.contributor.authorIlhan, Yusuf
dc.contributor.authorBalcik, Onur Yazdan
dc.contributor.authorGuzel, Halil Goksel
dc.contributor.authorOnder, Arif Hakan
dc.contributor.authorDemir, Bilgin
dc.contributor.authorBaser, Mehmet Nuri
dc.contributor.authorKaradag, Ibrahim
dc.date.accessioned2026-01-24T12:26:40Z
dc.date.available2026-01-24T12:26:40Z
dc.date.issued2025
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractBACKGROUND Metastatic colorectal cancer (mCRC) is a global health challenge with a poor prognosis. Prognostic markers are critical for survival prediction. AIM To evaluate a novel tumor marker index (TMI) combining carcinoembryonic antigen and carbohydrate antigen 19-9. METHODS This multicenter, retrospective study measured baseline carcinoembryonic antigen and carbohydrate antigen 19-9 levels to calculate a TMI as the geometric mean of values normalized to their upper limits of normal. Receiver operating characteristic curve analysis assessed TMI's prognostic accuracy, and patients were stratified into high-TMI (>= 1.39) and low-TMI (< 1.39) groups. The primary endpoint was overall survival (OS), with progression-free survival and treatment response as secondary endpoints. RESULTS The study included 305 mCRC patients with a median follow-up of 22.9 months. The median OS for high-TMI patients was 29.5 months, significantly lower than the 45.6 months observed in the low-TMI group (P = 0.02). The 2-year OS rates for the high- and low-TMI groups were 59.4% and 72.9%, respectively. Median progression-free survival was also shorter for the high-TMI group (14.0 vs 16.0 months, P = 0.84). High TMI is an independent prognostic factor for worse OS. CONCLUSION TMI is a simple, cost-effective prognostic tool for mCRC, with high TMI associated with poorer survival outcomes.
dc.identifier.doi10.4251/wjgo.v17.i5.104341
dc.identifier.issn1948-5204
dc.identifier.issue5
dc.identifier.pmid40487947
dc.identifier.scopus2-s2.0-105005341485
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.4251/wjgo.v17.i5.104341
dc.identifier.urihttps://hdl.handle.net/20.500.12868/4848
dc.identifier.volume17
dc.identifier.wosWOS:001498719600023
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBaishideng Publishing Group Inc
dc.relation.ispartofWorld Journal of Gastrointestinal Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260121
dc.subjectColorectal cancer biomarkers
dc.subjectMetastatic colorectal cancer
dc.subjectCarcinoembryonic antigen
dc.subjectCarbohydrate antigen 19-9
dc.subjectTumor marker index
dc.titleNovel tumor marker index combining carcinoembryonic antigen and carbohydrate antigen 19-9: New prognostic factor for metastatic colorectal cancer
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu